The Lonza CEO said the company is not under any pressure to exit the Capsules and Health Ingredients (CHI) business and is ...

Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao ...

The metaverse hype is over, but developer Cassette Group has been working with Pfizer to realise its forgotten potential.

IMPACT Therapeutics has received the China NMPA marketing authorisation for Senaparib capsules in treating ovarian cancer.

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...

Charles River and Akron Bio have announced the integration of the latter’s CSS liquid cytokines into the former's Cell ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

How longitudinal, closed claims data is advancing regulatory, epidemiology, and health economics and outcomes research (HEOR) ...

The radiopharmaceutical developer expanded its reach, acquiring R&D, isotope production, manufacturing, and distribution.

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...